CDK4 Amplification is an inclusion criterion in 2 clinical trials for liposarcoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 Amplification and liposarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [5].

Palbociclib has evidence of efficacy in patients with CDK4 Amplification in liposarcoma [5].

CDK4 Amplification is an inclusion criterion in 7 clinical trials for malignant solid tumor, of which 7 are open and 0 are closed. Of the trials that contain CDK4 Amplification and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (5 open) [5].

CDK4 Amplification is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 2 are open and 1 is closed. Of the trials that contain CDK4 Amplification and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 3 clinical trials for malignant glioma, of which 3 are open and 0 are closed. Of the trials that contain CDK4 Amplification and malignant glioma as inclusion criteria, 3 are early phase 1 (3 open) [5].

CDK4 Amplification is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 Amplification and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 Amplification and melanoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CDK4 Amplification is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 Amplification and non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CDK4 Amplification is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 Amplification and ovarian carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CDK4 Amplification is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 Amplification and soft tissue sarcoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for acral lentiginous melanoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and acral lentiginous melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains CDK4 Amplification and cancer as inclusion criteria, 1 is phase 2 (0 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for chordoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and chordoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for dedifferentiated chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and dedifferentiated chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for fallopian tube carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and fallopian tube carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and glioblastoma as inclusion criteria, 1 is early phase 1 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and leiomyosarcoma as inclusion criteria, 1 is phase 3 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and lung adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and meningioma as inclusion criteria, 1 is early phase 1 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and ovarian epithelial tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for primary peritoneal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and primary peritoneal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and squamous cell lung carcinoma as inclusion criteria, 1 is no phase specified (1 open) [5].